WP
SRPT icon

WealthPLAN Partners’s Sarepta Therapeutics SRPT Stock Holding History

WealthPLAN Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$6.15K Buy
+100
New +$3.02K ﹤0.01% 676

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

WealthPLAN Partners's SRPT Position: Q3 2016 in Review

WealthPLAN Partners opened a new position in Sarepta Therapeutics (SRPT) in Q3 2016: 100 shares worth $6.15K. The stake represents ﹤0.01% of the portfolio and ranks #676 among its holdings.

188 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

  • WealthPLAN Partners held 100 shares of Sarepta Therapeutics worth $6.15K as of Q3 2016.
  • Sarepta Therapeutics was a new WealthPLAN Partners position in Q3 2016.
  • Sarepta Therapeutics made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #676 holding.
  • 188 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.